TWI906955B - NF-κB誘導激酶之小分子抑制劑 - Google Patents

NF-κB誘導激酶之小分子抑制劑

Info

Publication number
TWI906955B
TWI906955B TW113125993A TW113125993A TWI906955B TW I906955 B TWI906955 B TW I906955B TW 113125993 A TW113125993 A TW 113125993A TW 113125993 A TW113125993 A TW 113125993A TW I906955 B TWI906955 B TW I906955B
Authority
TW
Taiwan
Prior art keywords
ethynyl
hydroxy
phenyl
pyrimidin
mmol
Prior art date
Application number
TW113125993A
Other languages
English (en)
Chinese (zh)
Other versions
TW202517638A (zh
Inventor
傑肯特 巴貝
文英 柴
溫蒂 艾寇斯
麥可 哈克
艾倫 赫曼
威廉 瓊斯
保羅 柯羅列克
凱文 柯魯特
艾利克 萊柏薩克
丹尼爾 皮普
亞歷山大 羅維拉
羅納德 沃林
Original Assignee
比利時商健生藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商健生藥品公司 filed Critical 比利時商健生藥品公司
Publication of TW202517638A publication Critical patent/TW202517638A/zh
Application granted granted Critical
Publication of TWI906955B publication Critical patent/TWI906955B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW113125993A 2019-05-31 2020-05-29 NF-κB誘導激酶之小分子抑制劑 TWI906955B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962855144P 2019-05-31 2019-05-31
US62/855,144 2019-05-31
US201962907833P 2019-09-30 2019-09-30
US62/907,833 2019-09-30

Publications (2)

Publication Number Publication Date
TW202517638A TW202517638A (zh) 2025-05-01
TWI906955B true TWI906955B (zh) 2025-12-01

Family

ID=71108552

Family Applications (2)

Application Number Title Priority Date Filing Date
TW113125993A TWI906955B (zh) 2019-05-31 2020-05-29 NF-κB誘導激酶之小分子抑制劑
TW109118004A TWI850390B (zh) 2019-05-31 2020-05-29 NF-κB誘導激酶之小分子抑制劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW109118004A TWI850390B (zh) 2019-05-31 2020-05-29 NF-κB誘導激酶之小分子抑制劑

Country Status (37)

Country Link
US (3) US11254673B2 (enExample)
EP (2) EP4467199A3 (enExample)
JP (2) JP7547387B2 (enExample)
KR (1) KR102995125B1 (enExample)
CN (2) CN114222737B (enExample)
AU (1) AU2020282005B2 (enExample)
BR (1) BR112021023796A2 (enExample)
CL (1) CL2021003142A1 (enExample)
CO (1) CO2021017838A2 (enExample)
CR (1) CR20210587A (enExample)
DK (1) DK3976597T3 (enExample)
DO (1) DOP2021000244A (enExample)
EC (1) ECSP21093623A (enExample)
ES (1) ES2989387T3 (enExample)
FI (1) FI3976597T3 (enExample)
HR (1) HRP20241352T1 (enExample)
HU (1) HUE068694T2 (enExample)
IL (1) IL288387B2 (enExample)
JO (1) JOP20210318B1 (enExample)
LT (1) LT3976597T (enExample)
MA (1) MA56038B1 (enExample)
MD (1) MD3976597T2 (enExample)
MX (1) MX2021014679A (enExample)
MY (1) MY205653A (enExample)
PE (1) PE20220768A1 (enExample)
PH (1) PH12021553011A1 (enExample)
PL (1) PL3976597T3 (enExample)
PT (1) PT3976597T (enExample)
RS (1) RS66105B1 (enExample)
SA (1) SA521430960B1 (enExample)
SG (1) SG11202112994WA (enExample)
SI (1) SI3976597T1 (enExample)
SM (1) SMT202400418T1 (enExample)
TW (2) TWI906955B (enExample)
UA (1) UA130430C2 (enExample)
UY (1) UY38721A (enExample)
WO (1) WO2020239999A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
BR112021024108A2 (pt) 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
CR20210587A (es) * 2019-05-31 2022-02-11 Janssen Pharmaceutica Nv Inhibidores de molécula pequeña de quinasa inductora de nf-kb
CA3257152A1 (en) * 2022-05-11 2023-11-16 Janssen Pharmaceutica Nv Pyrrolidine derivatives useful as NF-κB induction kinase inhibitors
JP2025516559A (ja) * 2022-05-11 2025-05-30 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｆ－カッパｂ誘導性キナーゼの阻害剤としてのピロリジオン（ｐｙｒｒｏｌｉｄｉｏｎｅ）誘導体
AU2023410324A1 (en) 2022-12-22 2025-05-15 Boehringer Ingelheim International Gmbh Crystalline forms of a her2 inhibitor
WO2025020886A1 (zh) * 2023-07-27 2025-01-30 浙江星浩澎博医药有限公司 氮杂喹唑啉环衍生物及其用途
CN121568696A (zh) 2023-07-28 2026-02-24 勃林格殷格翰国际有限公司 制备her2抑制剂的方法
WO2025235874A1 (en) * 2024-05-10 2025-11-13 Schrödinger, Inc. Heterocyclics as egfr inhibitors
WO2026029041A1 (ja) * 2024-07-30 2026-02-05 日本たばこ産業株式会社 ピラゾロピリミジン化合物及びその医薬用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200605886A (en) * 2004-08-03 2006-02-16 Wyeth Corp Indazoles useful in treating cardiovascular diseases
WO2009158011A1 (en) * 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2012123522A1 (en) * 2011-03-16 2012-09-20 F. Hoffmann-La Roche Ag 6,5-heterocyclic propargylic alcohol compounds and uses therefor
WO2018037058A1 (en) * 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
TWI850390B (zh) * 2019-05-31 2024-08-01 比利時商健生藥品公司 NF-κB誘導激酶之小分子抑制劑

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US7132428B2 (en) 2003-07-03 2006-11-07 Aventis Pharmaceuticals Inc. Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders
JP4828421B2 (ja) 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
MXPA06011423A (es) 2004-04-02 2007-01-23 Osi Pharm Inc Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
JP2008519850A (ja) 2004-11-10 2008-06-12 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２調節化合物
TWI368974B (en) 2004-11-12 2012-07-21 Chippac Inc Ball-on-trace wire bond interconnection
WO2010042337A1 (en) 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
AR089999A1 (es) * 2012-02-17 2014-10-01 Hoffmann La Roche Compuestos triciclicos y metodos para el uso de los mismos
US9159402B2 (en) 2012-07-02 2015-10-13 Stmicroelectronics International N.V. SRAM bitcell implemented in double gate technology
US8859553B2 (en) * 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
BR112015010225A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos e seus métodos de produção e utilização
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
JP2016533385A (ja) * 2013-08-22 2016-10-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アルキニルアルコール及び使用方法
WO2015025026A1 (en) * 2013-08-22 2015-02-26 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
EP4649963A3 (en) 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2016062792A1 (en) 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New compounds as nik inhibitors
AU2015334914B2 (en) 2014-10-23 2019-09-19 Janssen Pharmaceutica Nv New thienopyrimidine derivatives as NIK inhibitors
JP6616411B2 (ja) 2014-10-23 2019-12-04 ヤンセン ファーマシューティカ エヌ．ベー． 新規な、ｎｉｋ阻害剤としてのピラゾール誘導体
EA033237B1 (ru) 2014-10-23 2019-09-30 Янссен Фармацевтика Нв Новые производные пиразолопиримидина в качестве ингибиторов nik, фармацевтическая композиция и лекарственное средство, содержащее ее
WO2016135163A1 (en) 2015-02-25 2016-09-01 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
EP3405464B1 (en) 2016-01-22 2019-12-04 Janssen Pharmaceutica NV New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
HRP20200133T1 (hr) 2016-01-22 2020-05-15 Janssen Pharmaceutica Nv Novi supstituirani derivati cijanoindolina kao inhibitori nik
EP3478675B1 (en) 2016-06-30 2020-04-22 Janssen Pharmaceutica NV Heteroaromatic derivatives as nik inhibitors
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
JP7140751B2 (ja) 2016-08-24 2022-09-21 エフ．ホフマン－ラ ロシュ アーゲー ２－アザビシクロ［３．１．０］ヘキサン－３－オン誘導体及び使用方法
AU2018297592B2 (en) 2017-07-06 2021-12-16 Janssen Pharmaceutica Nv New substituted azaindoline derivatives as NIK inhibitors
CN109810110B (zh) * 2017-11-22 2023-01-24 中国科学院上海药物研究所 一种具有2-氨基嘧啶结构的化合物，其制备方法和用途
BR112021024108A2 (pt) 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド及びその組成物
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
MA56022A (fr) 2019-05-31 2022-04-06 Chiesi Farm Spa Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3
JP7559059B2 (ja) 2019-09-30 2024-10-01 インサイト・コーポレイション 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物
JP2025516564A (ja) 2022-05-11 2025-05-30 ヤンセン ファーマシューティカ エヌ．ベー． ＮＦ－κＢ誘導性キナーゼの阻害剤としてのピロリジノン誘導体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200605886A (en) * 2004-08-03 2006-02-16 Wyeth Corp Indazoles useful in treating cardiovascular diseases
WO2009158011A1 (en) * 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2012123522A1 (en) * 2011-03-16 2012-09-20 F. Hoffmann-La Roche Ag 6,5-heterocyclic propargylic alcohol compounds and uses therefor
WO2018037058A1 (en) * 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
TWI850390B (zh) * 2019-05-31 2024-08-01 比利時商健生藥品公司 NF-κB誘導激酶之小分子抑制劑

Also Published As

Publication number Publication date
IL288387B2 (en) 2026-01-01
CL2021003142A1 (es) 2022-08-19
US12617789B2 (en) 2026-05-05
BR112021023796A2 (pt) 2022-02-08
MA56038B1 (fr) 2024-11-29
IL288387B1 (en) 2025-09-01
HUE068694T2 (hu) 2025-01-28
US20230080834A1 (en) 2023-03-16
LT3976597T (lt) 2024-10-10
CR20210587A (es) 2022-02-11
SMT202400418T1 (it) 2024-11-15
MD3976597T2 (ro) 2025-01-31
EP3976597A1 (en) 2022-04-06
PH12021553011A1 (en) 2022-11-07
AU2020282005A1 (en) 2021-12-23
DK3976597T3 (da) 2024-09-09
PT3976597T (pt) 2024-10-22
MY205653A (en) 2024-11-02
JP7547387B2 (ja) 2024-09-09
FI3976597T3 (fi) 2024-09-25
UY38721A (es) 2020-11-30
SA521430960B1 (ar) 2024-11-12
PL3976597T3 (pl) 2024-12-16
JOP20210318B1 (ar) 2025-10-01
JOP20210318A1 (ar) 2023-01-30
JP7872322B2 (ja) 2026-06-09
TW202517638A (zh) 2025-05-01
CN118908957A (zh) 2024-11-08
JP2024167319A (ja) 2024-12-03
AU2020282005B2 (en) 2026-02-12
ECSP21093623A (es) 2022-01-31
KR102995125B1 (ko) 2026-07-23
MX2021014679A (es) 2022-04-06
WO2020239999A1 (en) 2020-12-03
IL288387A (en) 2022-01-01
PE20220768A1 (es) 2022-05-16
US20240199605A1 (en) 2024-06-20
SI3976597T1 (sl) 2024-11-29
ES2989387T3 (es) 2024-11-26
HRP20241352T1 (hr) 2024-12-20
DOP2021000244A (es) 2022-04-18
EP4467199A3 (en) 2025-03-05
US11827634B2 (en) 2023-11-28
US11254673B2 (en) 2022-02-22
SG11202112994WA (en) 2021-12-30
TW202110842A (zh) 2021-03-16
JP2022534302A (ja) 2022-07-28
TWI850390B (zh) 2024-08-01
EP3976597B1 (en) 2024-08-28
RS66105B1 (sr) 2024-11-29
US20210300918A1 (en) 2021-09-30
EP4467199A2 (en) 2024-11-27
CN114222737B (zh) 2024-07-26
CO2021017838A2 (es) 2022-01-17
KR20220027871A (ko) 2022-03-08
CA3143350A1 (en) 2020-12-03
UA130430C2 (uk) 2026-02-18
CN114222737A (zh) 2022-03-22
MA56038A (fr) 2022-04-06

Similar Documents

Publication Publication Date Title
TWI850390B (zh) NF-κB誘導激酶之小分子抑制劑
EP4067347B1 (en) Heterocyclic inhibitors of cbp/ep300 for the treatment of cancer
ES2908412T3 (es) Derivados de piperidin-4-IL azetidina como inhibidores de JAK1
TW202434582A (zh) Ｓｏｓ１抑制劑
TW201130852A (en) Novel thienopyrrole compounds
AU2020324561A1 (en) Quinoline derivatives as protein kinase inhibitors
JP2022547915A (ja) Ａｘｌとｃ－Ｍｅｔキナーゼ阻害活性を有する化合物およびその製造と使用
KR20230069169A (ko) 카제인 키나제 1 델타 조절제
CN113429427A (zh) 杂环化合物及其制备方法和药物用途
EP4244224A1 (en) Small molecule inhibitors of nf-kb inducing kinase
CA3143350C (en) Small molecule inhibitors of nf-kb inducing kinase
HK40119602A (en) Small molecule inhibitors of nf-kb inducing kinase
EA045720B1 (ru) НИЗКОМОЛЕКУЛЯРНЫЕ ИНГИБИТОРЫ NF-κB-ИНДУЦИРУЮЩЕЙ КИНАЗЫ
HK40071178B (en) Small molecule inhibitors of nf-kb inducing kinase
HK40071178A (en) Small molecule inhibitors of nf-kb inducing kinase
CN110612302B (zh) 作为激酶JAK抑制剂的吡唑并[1,5-a]嘧啶衍生物
JP2025516597A (ja) Ｎｆカッパｂ誘導性キナーゼの阻害剤としてのピロリジノン誘導体